Merida Biosciences
Phase 3Current treatments for autoimmune diseases are non-specific, often have poor efficacy and come with a risk of serious side effects. Our novel platform aims to target and eliminate the pathogenic drivers of antibody-driven diseases with unprecedented precision and durability to address the root cause of disease and achieve durable clinical responses.
Private Company
Funding information not available
About
Current treatments for autoimmune diseases are non-specific, often have poor efficacy and come with a risk of serious side effects. Our novel platform aims to target and eliminate the pathogenic drivers of antibody-driven diseases with unprecedented precision and durability to address the root cause of disease and achieve durable clinical responses.